For a 30‑year‑old patient with narcolepsy, prior respiratory depression with low‑dose sodium oxybate (Xywav), ongoing excessive daytime sleepiness on armodafinil, bupropion, gabapentin, duloxetine, fluoxetine, and minor cataplexy, should I initiate solriamfetol (Sunosi) or pitolisant rather than restarting Xywav?

Avoid Restarting Xywav and Initiate Solriamfetol (Sunosi) as First-Line

Given this patient's documented respiratory depression with Xywav and persistent excessive daytime sleepiness despite armodafinil 250 mg, you should initiate solriamfetol (Sunosi) rather than pitolisant or retry sodium oxybate formulations. The prior respiratory depression with low-dose Xywav represents a serious safety signal that contraindicates any sodium oxybate rechallenge, regardless of formulation.

Rationale for Solriamfetol Over Pitolisant

Solriamfetol (Sunosi) - Preferred Choice

The 2021 American Academy of Sleep Medicine guidelines provide STRONG recommendations for both solriamfetol and pitolisant in narcolepsy 1. However, solriamfetol has distinct advantages for this patient:

• Higher quality evidence: Solriamfetol demonstrated high-quality evidence (versus moderate for pitolisant) with 3 RCTs showing clinically significant improvements in excessive daytime sleepiness and disease severity 1
• Superior efficacy data: Recent 2025 network meta-analysis shows solriamfetol 300 mg was more effective than other treatments in reducing ESS scores (MD = -4.74) and prolonging sleep latency (MD = 10.82 min) 2
• Complementary mechanism: As a dopamine and norepinephrine reuptake inhibitor, solriamfetol provides a different mechanism than the armodafinil she's already taking, potentially offering additive benefit 3, 4
• No respiratory depression risk: Unlike sodium oxybate, solriamfetol does not carry CNS depressant effects 3

Practical Dosing for This Patient

Start solriamfetol at 75 mg once daily upon awakening for narcolepsy 3. Key considerations:

• Titrate by doubling the dose at 3-day intervals based on response
• Maximum dose is 150 mg daily
• Administer upon awakening, avoid within 9 hours of bedtime
• Critical: Assess and control blood pressure before initiating, as solriamfetol increases BP and heart rate dose-dependently 3

Why Not Pitolisant?

While pitolisant also carries a STRONG recommendation 1, it has several disadvantages in this context:

• Only moderate quality evidence from 3 RCTs 1
• Available only through specialty pharmacies, creating access barriers 1
• May reduce effectiveness of oral contraception (relevant for 30-year-old female) 1
• Network meta-analysis showed pitolisant had highest risk of nausea among wake-promoting agents 2

Critical Safety Consideration: Sodium Oxybate is Contraindicated

Do not retry any sodium oxybate formulation (Xywav, Xyrem, or low-sodium oxybate) in this patient. The documented respiratory depression represents a serious adverse event, and sodium oxybate carries an FDA black box warning for CNS depression and respiratory depression 1. This risk is particularly concerning given her:

• History of respiratory depression with prior Xywav trial
• Concurrent CNS-active medications (gabapentin 900 mg, duloxetine 120 mg, fluoxetine 50 mg, risperidone)
• Possible POTS (autonomic instability may increase vulnerability)

The combination of gabapentin (a CNS depressant) with sodium oxybate compounds respiratory depression risk significantly.

Addressing Her Complex Medication Regimen

Before adding solriamfetol, consider:

1. Gabapentin timing: Moving gabapentin earlier in the evening (as planned) will reduce morning sedation that compounds her EDS
2. Polypharmacy burden: She's on multiple CNS-active medications (gabapentin, duloxetine, fluoxetine, risperidone, bupropion, armodafinil). The sedating effects of gabapentin, duloxetine at night, and risperidone likely contribute to her persistent sleepiness
3. Blood pressure monitoring: Essential before and during solriamfetol treatment, especially given potential POTS 3

Monitoring Plan

After initiating solriamfetol:

• Assess blood pressure at baseline and regularly during treatment 3
• Monitor for common adverse effects: headache, decreased appetite, insomnia, nausea, chest discomfort 1
• Reassess ESS score at 2-4 weeks
• If inadequate response at 75 mg after 3+ days, increase to 150 mg
• Consider whether armodafinil can be reduced or discontinued once solriamfetol is optimized

Minor Cataplexy Management

Her minor cataplexy (leg buckling, neck weakness) is currently not severe. If cataplexy worsens or becomes more problematic:

• Venlafaxine or other SNRIs/SSRIs (she's already on duloxetine and fluoxetine) have STRONG recommendations for cataplexy 1
• Pitolisant has a WEAK recommendation for cataplexy but could be considered if solriamfetol alone is insufficient 1
• Sodium oxybate remains contraindicated despite its strong efficacy for cataplexy given her prior respiratory depression

The clear choice is solriamfetol 75 mg daily, titrating to 150 mg as tolerated, while optimizing her current medication timing and monitoring blood pressure closely.